Navigation Links
Drug could reverse scourge of cerebral malaria for survivors
Date:5/1/2012

ncet Neurology.

The new clinical trial will test the safety and feasibility of LVT to control seizures in children specifically with cerebral malaria. Instead of delivering the drug intravenously, which is too costly for most developing nations such as Malawi, it will be given via a tube in the nasal passage, an effective method in hospitals and clinics that lack resources.

About 40 children will be selected for the trial. If all safety standards are met, dosage will be increased until 75 percent of children are free of seizures for 24 hours (typically, only 20 percent of children admitted with cerebral malaria and seizures are seizure free in the first 24 hours).

To accurately test whether children are staying seizure free, MSU is collaborating with New York-based biotechnology firm Bio-Signal Group, which has created a portable, wireless EEG monitoring device, called microEEG that can accommodate up to 32 electrodes and connects via Bluetooth technology to a small monitoring machine.

"Unfortunately, many children who survive malaria continue to have seizures with no physical symptoms, but their brains still are being damaged," Birbeck said. "To evaluate the effectiveness of LVT, we need continuous EEG monitoring, which is very tough to do even in the best environment."

Bio-Signal's microEEG features a monitor the size of a deck of cards that can be worn on the arm, with a collection of wires going to the electrodes on the child's head. The monitor then transfers data in real-time to a computer, where it quickly can be analyzed and shared with colleagues.

"This state-of-the-art technology, which we believe can be used effectively in our resource-limited setting, allows us to conduct this trial," Birbeck said.

If the clinical trial shows LVT can be safe and potentially effective for seizure control in cerebral malaria, Birbeck and her team will proceed with a phase III randomized clinical trial.
'/>"/>

Contact: Jason Cody
codyja@msu.edu
517-432-0924
Michigan State University
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Vitiligo skin disorder could yield clues in fight against melanoma
2. Saliva proteins could help detection of oral cancer
3. Research about plant viruses could lead to new ways to improve crop yields
4. Nanodiamond drug device could transform cancer treatment
5. UNC study on properties of carbon nanotubes, water could have wide-ranging implications
6. So-called sandfish could help materials handling and process technology specialists
7. Discovery of natural compounds that could slow blood vessel growth
8. Researchers design artificial cells that could power medical implants
9. Herbicide-resistant grape could revitalize Midwest wine industry
10. Sensitive laser instrument could aid search for life on Mars
11. Could Dr. House be replaced by a computer?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug could reverse scourge of cerebral malaria for survivors
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial Hospital ... to implant a new miniaturized, wireless monitoring sensor to ... the first and only FDA-approved heart failure monitoring device ... when used by physicians to manage heart failure. ... is implanted in the pulmonary artery (PA) during a ...
(Date:4/17/2015)... April 17, 2015 ... and technological advancement to drive biometric systems market ... 2020   According to a recently ... Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... register growth at CAGR of over 22% through ...
(Date:4/14/2015)... Conn. , April 14, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... been nominated for the 2015 New York Design Awards ... The Design100, New York City Design Awards are part ... based on over 2,500 ratings from the marketplace, industry ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... Mexican oregano, all contain apigenin and luteolin, flavonoids that ... inhibiting an important enzyme, according to two new University ... in two aggressive human pancreatic cancer cell lines. But ... cells with apigenin for 24 hours, then applied the ...
... BOSTON (August 15, 2013) -- In a study published ... Molecular Genetics , Drs. Donita Garland, Rosario Fernandez-Godino, and ... Massachusetts Eye and Ear, Harvard Medical School, along with ... genetically engineered to have an inherited form of macular ...
... MEDFORD/SOMERVILLE, Mass. In two recently published papers, ... techniques for predicting the severity of seasonal cholera epidemics ... of accuracy than other methods based on remote ... may provide the essential lead time to strengthen intervention ...
Cached Biology News:Celery, artichokes contain flavonoids that kill human pancreatic cancer cells 2Researchers report a critical role for the complement system in early macular degeneration 2Researchers report a critical role for the complement system in early macular degeneration 3Tufts scientists develop new early warning system for cholera epidemics 2Tufts scientists develop new early warning system for cholera epidemics 3
(Date:5/1/2015)... 2015 Pfenex Inc. (NYSE MKT: PFNX), ... of biosimilar therapeutics including high value and difficult ... quarter 2015 financial results will be released on ... market. At 8:30 am Eastern Time, Pfenex management will ... results and provide a business update. A press release ...
(Date:5/1/2015)... -- According to a new market ... by Type (Monoclonal, Polyclonal), by Technology (Hybridoma), by ... Analysis & Global Forecast to 2019", published by ... Market for the forecast period of 2014 to ... Billion by 2019 from $1.425 Billion in 2014, ...
(Date:4/30/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) reported total research ... $4.4 million, compared to $8.0 million during the same period ... was $8.9 million, or $0.23 per basic and diluted share. ... period in 2014, of $8.7 million, or $0.27 per basic ... cash equivalents and investments totaled $117.5 million. , "During ...
(Date:4/30/2015)... Cambridge, MA & Budapest, Hungary (PRWEB) April 30, ... the only web-based electronic lab notebook with integrated ... leader in providing chemistry software solutions and consulting ... that led to the development of Labguru’s newest ... a set of deep domain features for biologists, ...
Breaking Biology Technology:Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2
... Richard Gabriel, Chief,Executive Officer of DNAPrint Genomics, ... be featured in an exclusive interview with, http://www.wallst.net ... September 10 at 11,a.m. EDT. The interview will ... p.m.,EDT on September 10. The interview will ...
... Alba Therapeutics Corporation today,announced the appointment of ... Clinical Development and Medical Affairs. In this role, ... clinical development strategy,and program execution through product approval ... a member of Alba,s executive management,leadership team. ...
... /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX:,ARI), a biotechnology ... therapeutics, today announced that it will deliver poster,presentations ... of its anti-cancer antibody drug candidates. At ... on September 7-8,Arius will report recent results of ...
Cached Biology Technology:WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics 2Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs 2Arius Features Preclinical Data on Antibody Candidates at Two Conferences 2Arius Features Preclinical Data on Antibody Candidates at Two Conferences 3
... liter of urine will give a positive reaction ... ,Certification: The Donors are of US origin ... NEGATIVE for HbsAg, HCV, HIV-1 & 2, Syphilis ... THIS MATERIAL IS SOLD FOR IN-VITRO DIAGNOSTIC USE ...
... Identical to the DH-2000, except that it ... 190-1700 nm wavelength range and comes with a ... up to 5 Hz) The DH-2000 ... spectrum of deuterium and tungsten halogen light sources ...
... pump is a dedicated cuff pump for small ... replaces manual inflation and can be used for ... mouse and rat; from single up to multi-channel ... pump has adjustable cut-off pressure in 50 mmHg ...
... These handy dispensers save space ... hats, and other garb. They are ... small parts used in labs, processing ... static charges and the particles they ...
Biology Products: